+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diabetic nephropathy Market by Therapeutic Agents, Diagnostic Solutions, Distribution Channel, End User, Stage of Disease, Route of Administration - Global Forecast to 2030- Product Image
Diabetic nephropathy Market by Therapeutic Agents, Diagnostic Solutions, Distribution Channel, End User, Stage of Disease, Route of Administration - Global Forecast to 2030- Product Image
Sale

Diabetic nephropathy Market by Therapeutic Agents, Diagnostic Solutions, Distribution Channel, End User, Stage of Disease, Route of Administration - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6015431
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The diabetic nephropathy market is undergoing rapid transformation as healthcare stakeholders address rising disease prevalence and evolving standards of care. Against the backdrop of increasing patient populations, new clinical paradigms, and a complex regulatory environment, strategic foresight is essential for organizations seeking to capitalize on growth opportunities and manage operational risks.

Market Snapshot: Diabetic Nephropathy Market Overview

The diabetic nephropathy market grew from USD 2.93 billion in 2024 to USD 3.12 billion in 2025. It is expected to continue growing at a CAGR of 6.33%, reaching USD 4.24 billion by 2030.

Scope & Segmentation

  • Therapeutic Agents: ACE inhibitors (including enalapril, lisinopril, ramipril), angiotensin receptor blockers (irbesartan, losartan, valsartan), diuretics (loop, thiazide, potassium-sparing types), endothelin receptor antagonists (ambrisentan, bosentan, macitentan), and SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin).
  • Diagnostic Solutions: Biomarker testing (albuminuria testing, GFR assessment), imaging via CT, MRI, and ultrasound, along with traditional kidney biopsy.
  • Distribution Channels: Hospital pharmacies, retail pharmacies, and online pharmacies address different market access requirements and support diverse purchasing models.
  • End Users: Diagnostic centers, hospitals, home care settings, and specialty clinics, each with distinct adoption dynamics and decision processes.
  • Stage of Disease: Segmented by early, moderate, advanced, and end stage renal disease, influencing therapy types and monitoring frequency.
  • Route of Administration: Oral, intravenous, and subcutaneous delivery channels offer flexibility to match patient needs and resource settings.
  • Geographic Regions: Coverage includes Americas (with specific focus on U.S. states like California and Texas), Europe, Middle East & Africa (including Germany, France, UAE, South Africa, and more), and Asia-Pacific (notably China, India, Japan, and Australia).
  • Technology Integration: Innovations such as precision diagnostics, digital health platforms, advanced imaging, and remote monitoring technologies shape market direction and value creation.
  • Leading Companies: Boehringer Ingelheim International GmbH, Eli Lilly and Company, AstraZeneca PLC, Bayer AG, and Novo Nordisk A/S actively drive R&D and market differentiation.

Key Takeaways for Senior Decision-Makers

  • SGLT2 inhibitors are now central to diabetic nephropathy management, elevating the standard of renal care and prompting updated clinical guidelines.
  • Precision medicine strategies leveraging biomarker-driven testing improve early detection, personalize interventions, and reduce progression to severe disease states.
  • Collaborative regulatory pathways and health authority engagement are expediting the adoption of novel agents and fostering industry-healthcare alliances.
  • Value-based contracting is reshaping payer-provider relationships, aligning reimbursement with real-world therapeutic outcomes and encouraging strategic investments.
  • Integration of digital health and advanced imaging solutions supports individualized dosing, continuous monitoring, and streamlined diagnostic workflows.
  • Regional growth is shaped by reimbursement frameworks, infrastructure investment, and evolving care delivery models unique to each major geography.

Impact of US Tariffs on Market Equilibrium

The 2025 introduction of U.S. tariffs on select active pharmaceutical ingredients and medical device components is intensifying supply chain challenges across therapeutic and diagnostic subsectors. Manufacturers of ACE inhibitors, diuretics, and SGLT2 inhibitors are navigating input cost pressures through revised sourcing strategies and forward contracts. Supply disruptions extend to diagnostic firms as imaging equipment and biomarker testing reagents become costlier and less predictable to procure. Stakeholders are exploring onshoring, expanded regional distribution hubs, and long-term supplier agreements to stabilize availability and absorb price volatility. As a result, cost optimization now weighs equally alongside efficacy and clinical utility in product adoption decisions.

Methodology & Data Sources

This report’s strategic insights derive from secondary research spanning peer-reviewed literature, regulatory filings, annual reports, and white papers, complemented by interviews with over 50 nephrologists, endocrinologists, payers, and advocacy leaders. Quantitative validation leverages proprietary sales, adoption, and channel-performance databases, with expert panel triangulation ensuring data consistency and interpretive accuracy.

Why This Report Matters

  • Delivers actionable intelligence for optimizing market access, risk management, and investment decisions within diabetic nephropathy treatment and diagnostics.
  • Enables stakeholders to benchmark innovation, regulatory developments, and regional dynamics against peers and competitive benchmarks.
  • Offers guidance for aligning commercialization, R&D, and supply chain initiatives to evolving payer and clinical expectations.

Conclusion

This executive summary equips leadership teams to navigate the shifting diabetic nephropathy market landscape with clarity and confidence. The insights provided support informed planning, opportunity identification, and sustained value delivery in an evolving clinical and commercial environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Diabetic nephropathy Market, by Therapeutic Agents
8.1. Introduction
8.2. Ace Inhibitors
8.2.1. Enalapril
8.2.2. Lisinopril
8.2.3. Ramipril
8.3. Angiotensin Receptor Blockers
8.3.1. Irbesartan
8.3.2. Losartan
8.3.3. Valsartan
8.4. Diuretics
8.4.1. Loop Diuretics
8.4.2. Potassium Sparing Diuretics
8.4.3. Thiazide Diuretics
8.5. Endothelin Receptor Antagonists
8.5.1. Ambrisentan
8.5.2. Bosentan
8.5.3. Macitentan
8.6. Sglt2 Inhibitors
8.6.1. Canagliflozin
8.6.2. Dapagliflozin
8.6.3. Empagliflozin
9. Diabetic nephropathy Market, by Diagnostic Solutions
9.1. Introduction
9.2. Biomarker Testing
9.2.1. Albuminuria Test
9.2.2. Gfr Assessment
9.3. Imaging Solutions
9.3.1. Ct Scan
9.3.2. Mri
9.3.3. Ultrasound
9.4. Kidney Biopsy
10. Diabetic nephropathy Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Diabetic nephropathy Market, by End User
11.1. Introduction
11.2. Diagnostic Centers
11.3. Home Care Settings
11.4. Hospitals
11.5. Specialty Clinics
12. Diabetic nephropathy Market, by Stage of Disease
12.1. Introduction
12.2. Advanced Stage
12.2.1. Stage 4
12.3. Early Stage
12.3.1. Stage 1
12.3.2. Stage 2
12.4. End Stage Renal Disease
12.4.1. Dialysis
12.4.2. Transplant
12.5. Moderate Stage
12.5.1. Stage 3
13. Diabetic nephropathy Market, by Route of Administration
13.1. Introduction
13.2. Intravenous
13.3. Oral
13.4. Subcutaneous
14. Americas Diabetic nephropathy Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Diabetic nephropathy Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Diabetic nephropathy Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Boehringer Ingelheim International GmbH
17.3.2. Eli Lilly and Company
17.3.3. AstraZeneca PLC
17.3.4. Bayer AG
17.3.5. Novo Nordisk a/S
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. DIABETIC NEPHROPATHY MARKET MULTI-CURRENCY
FIGURE 2. DIABETIC NEPHROPATHY MARKET MULTI-LANGUAGE
FIGURE 3. DIABETIC NEPHROPATHY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. DIABETIC NEPHROPATHY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. DIABETIC NEPHROPATHY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DIABETIC NEPHROPATHY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ENALAPRIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY LISINOPRIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY RAMIPRIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY IRBESARTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY LOSARTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY VALSARTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY LOOP DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY POTASSIUM SPARING DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY THIAZIDE DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY AMBRISENTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY BOSENTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY MACITENTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY CANAGLIFLOZIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DAPAGLIFLOZIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY EMPAGLIFLOZIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ALBUMINURIA TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY GFR ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY KIDNEY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE 4, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE 1, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE 2, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY END STAGE RENAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY END STAGE RENAL DISEASE, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY MODERATE STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE 3, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY MODERATE STAGE, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY END STAGE RENAL DISEASE, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY MODERATE STAGE, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY END STAGE RENAL DISEASE, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY MODERATE STAGE, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 107. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 108. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 110. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 111. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 112. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 113. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 114. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 115. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 116. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 119. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 120. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 121. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY END STAGE RENAL DISEASE, 2018-2030 (USD MILLION)
TABLE 122. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY MODERATE STAGE, 2018-2030 (USD MILLION)
TABLE 123. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 125. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 126. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 127. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 128. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 129. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 131. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 132. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 133. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 136. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 137. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 138. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY END STAGE RENAL DISEASE, 2018-2030 (USD MILLION)
TABLE 139. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY MODERATE STAGE, 2018-2030 (USD MILLION)
TABLE 140. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY END STAGE RENAL DISEASE, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY MODERATE STAGE, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY END STAGE RENAL DISEASE, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY MODERATE STAGE, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY END STAGE RENAL DISEASE, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY MODERATE STAGE, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY END STAGE RENAL DISEASE, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY MODERATE STAGE, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 211. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 212. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 213. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 214. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 215. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 217. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 218. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 219. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 222. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 223. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 224. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY END STAGE RENAL DISEASE, 2018-2030 (USD MILLION)
TABLE 225. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY MODERATE STAGE, 2018-2030 (USD MILLION)
TABLE 226. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 228. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 229. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 230. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 231. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 232. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 233. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 234. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 235. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 236. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 239. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 240. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 241. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY END STAGE RENAL DISEASE, 2018-2030 (USD MILLION)
TABLE 242. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY MODERATE STAGE, 2018-2030 (USD MILLION)
TABLE 243. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 245. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 246. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 247. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 248. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 249. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 251. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 252. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 253. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 256. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY END STAGE RENAL DISEASE, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY MODERATE STAGE, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 262. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 263. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 264. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 265. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 266. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 267. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 268. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 269. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 270. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 273. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 274. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 275. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY END STAGE RENAL DISEASE, 2018-2030 (USD MILLION)
TABLE 276. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY MODERATE STAGE, 2018-2030 (USD MILLION)
TABLE 277. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 279. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 280. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 281. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 282. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 283. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 284. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 285. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 286. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 287. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 288. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 290. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 291. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 292. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY END STAGE RENAL DISEASE, 2018-2030 (USD MILLION)
TABLE 293. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY MODERATE STAGE, 2018-2030 (USD MILLION)
TABLE 294. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY END STAGE RENAL DISEASE, 2018-2030 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY MODERATE STAGE, 2018-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 312. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 314. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 316. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 318. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIAGNOSTIC SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 320. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY IMAGING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 322. SAUD

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Diabetic nephropathy market report include:
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Bayer AG
  • Novo Nordisk A/S

Table Information

Report AttributeDetails
No. of Pages193
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.12 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.24 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned6

Related Topics

Related Reports

Diabetic Nephropathy - Global Clinical Trials Review, 2025 - Product Image

Diabetic Nephropathy - Global Clinical Trials Review, 2025

  • Clinical Trials
  • 615 Pages
  • Global
From
Diabetic Nephropathy Treatment Market by Treatment Type, Distribution Channel, Route Of Administration, Disease Stage, Patient Population - Global Forecast to 2030 - Product Image

Diabetic Nephropathy Treatment Market by Treatment Type, Distribution Channel, Route Of Administration, Disease Stage, Patient Population - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Diabetic Nephropathy Treatment - Global Strategic Business Report - Product Image

Diabetic Nephropathy Treatment - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Diabetic Nephropathy- Pipeline Insight, 2025 - Product Image

Diabetic Nephropathy- Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
IgA Nephropathy Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

IgA Nephropathy Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 150 Pages
  • Global
From

About the Diabetic Nephropathy Drug Market

Diabetic Nephropathy is a type of kidney disease caused by diabetes. It is a major complication of diabetes and is the leading cause of end-stage renal disease. Endocrine and Metabolic Disorders Drugs are used to treat this condition. These drugs are used to reduce the risk of kidney damage, control blood sugar levels, and reduce the risk of cardiovascular disease. Commonly used drugs include ACE inhibitors, angiotensin receptor blockers, diuretics, and statins. Other drugs used to treat diabetic nephropathy include calcium channel blockers, alpha-glucosidase inhibitors, and insulin sensitizers. The Diabetic Nephropathy Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Novartis, Merck, Pfizer, Sanofi, AstraZeneca, and Bristol-Myers Squibb. Other companies in the market include Eli Lilly, GlaxoSmithKline, Boehringer Ingelheim, and Takeda Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.